well the obvious difference is in performance. They didn't even apply to be a class 2 with fda. Yes, they may improve over time, but any successful model is going to face competition eventually. RAP has a very solid advantage in being diagnostically capable already
- Forums
- ASX - By Stock
- RAP
- Ann: At-Home Obstructive Sleep Apnoea Study Update
Ann: At-Home Obstructive Sleep Apnoea Study Update, page-200
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)